Date:4/26/2012

e company's financial performance, because the company's management uses these measures internally for forecasting, budgeting and measuring its operating performance. In addition, the company believes that including EBITDA and supplemental adjustments applied in presenting adjusted EBITDA pursuant to our credit agreement is appropriate to provide additional information to investors to demonstrate the company's ability to comply with financial debt covenants (which are calculated using a measure similar to adjusted EBITDA) and assess the company's ability to incur additional indebtedness. Whenever Mylan uses such a non-GAAP measure, it will provide a reconciliation of non-GAAP financial measures to the most closely applicable GAAP financial measure. Investors and other readers are encouraged to review the related GAAP financial measures and the reconciliation of non-GAAP measures to their most closely applicable GAAP measure set forth below and should consider non-GAAP measures only as a supplement to, not as a substitute for or as a superior measure to, measures of financial performance prepared in accordance with GAAP.

Below is a reconciliation of GAAP net earnings attributable to Mylan Inc. and diluted GAAP EPS to adjusted net earnings attributable to Mylan Inc. and adjusted diluted EPS for the quarters ended March 31, 2012 and 2011 (in millions, except per share amounts): Three months ended March 31,20122011GAAP net earnings attributable to Mylan Inc. and diluted GAAP EPS

$
29.1

$
.30$
4.2

$
.23Purchase accounting related amortization (included in cost of sales) 

89.586.7Litigation settlements, net

2.224.0Interest expense, primarily amortization of convertible debt discount

13.311.9Non-cash accretion of contingent consideration liability

8.2-Clean energy investment subsidiary revenue (a)

(8.7)-Restructuring & other special items in
'/>"/>

SOURCE Mylan Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13
Related medicine technology :

1. Mylan and Pfizer Announce Epinephrine Auto-injector Settlement Agreement with Teva
2. Mylan Launches Generic Version of Zyprexa® Tablets
3. Mylan Launches First Generic Version of Lescol® Capsules
4. Mylan Schedules First Quarter 2012 Financial Results Conference Call and Live Webcast
5. Mylan One of First to Launch Generic Version of Boniva®
6. Mylan Canada Receives Health Canada Approval for Generic Version of Crestor®
7. Mylan Continues to Pursue Damages and Injunction Against Sunovions Brovana® in Ongoing Litigation
8. Mylan Pharmaceuticals President Tony Mauro Elected Chairman of GPhA
9. Mylan Secures an Additional $300 Million of Committed Financing
10. Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over Prior Year
11. Mylan and Pfizer Announce Epinephrine Auto-injector Settlement Agreement